Innovation Pharmaceuticals Inc (IPIX)

[BooDog]

$IPIX is motivated and working to utilize every resource they can on a very limited budget. Many companies utilize outside sources (i.e. PR firms) to get the word out. And many have someone, still not an insider, to write company PR's for them. I guess the only reason I even mentioned the article was compensated in my first mention of the article is because I knew this board would exploit it anyway. It's a non issue and the reason why there are disclosure laws. Especially for a small start-up otc. And yes, the MFO is also motivated as well and could have easily had Baystreet write the article. The affiliation between IPIX's regular writers could be with Baystreet as well. Not hard to imagine in this sector at all.
The truth is, it was very well written and compares two companies and show how undervalued we are. Yes, I agree our current financing has a great deal to do with why the PPS is where it is. And it can still change overnight if IPIX follows through with the first deal that not only gives them the funding to move forward but also provides that 3rd party validation. And if it's a good deal? This puppy certainly won't be under .20.

Message in reply to:

Hmmm. This language underscoring the article stood out for me...

"Baystreet.ca has been compensated one thousand eight hundred dollars by a third party for Innovation Pharmaceuticals advertising."


If they have to "advertise" with that type of group, we are in big trouble.

Posted by: farrell90
In reply to: BooDog who wrote msg# 253309 Date:1/4/2019 12:41:08 AM
Post #253377 of 253378


"Third party compensation for advertising"

JMO but we seem to need a little push to start our run up.

I am grateful for the help and pleasantly surprised someone would pay for the report.

God bless us, everyone

Farrell

Re the Galera/IPIX advertisement, Galera is a privately held company. Maybe they will want to go public and can buy IPIX's shell or merge with IPIX. Or at minimum, maybe Leo can persuade the Galera Angels to provide some financing for IPIX.

This would be excellent indeed.

Posted by: Lemoncat
In reply to: None Date:1/3/2019 9:06:02 PM
Post #253363 of 253378


Sometimes it helps to looks at some of the good deals that took place on pipeline assets at similar stages to Brilacidin (two indications ready for phase 3, multiple preparing for phase 2)

https://www.formatherapeutics.com/wp-content/uploads/2017/11/Top_10_Hit_Parade_EndPoints_NOV2017_2.pdf

Some real whoppers in there and we're very competitive to some of the assets scooped up there.

It's also nice to see some preclinical deal numbers:

https://ceoworld.biz/2017/12/05/a-review-of-preclinical-deals-in-2017/

It clearly highlights how a phase 2 (or even phase 1) is not necessary to sign a deal much greater than our current market cap.

Good stuff. Good night.

Posted by: farrell90
In reply to: georgejjl who wrote msg# 253371 Date:1/4/2019 12:28:21 AM
Post #253376 of 253378


Georgii, thanks for the reminder....Kevetrin's preclinical in vitro studies suggested reactivated P53 in Glioblastoma cells.

Kevetrin's stage 1 FDA study demonstrated superior safety compared to Roche's Nutlins, including RG7833 ,its latest P 53 activating drug.

Hopefully a partner is on the way [? Roche] so Kevetrin can be further studied.

GLTA Farrell

https://www.biospace.com/article/releases/cellceutix-adds-brain-cancer-to-growing-list-of-indications-for-its-novel-cancer-drug-/

"Results from the Company's latest in vitro research activities have shown that treatment of glioblastoma cell line (U-87 MG) with Kevetrin™ reactivates p53. The p53 signaling pathway is a crucial regulator of cell cycle and apoptosis. Remarkably, the p53 signaling pathway is defective in most, if not all, human tumors. In U-87 MG, Kevetrin™ activated p53 which induced the expression of p21 that acts as inhibitor of cell cycle progression. Activated p53 also triggered apoptosis by inducing expression of PUMA."

http://www.bloodjournal.org/content/124/21/116

"One DLT of prolonged myelosuppression was reported. RP2D is 1200 mg/d (600 mg bid) x 5 d q28d for both mono- and combination therapy due to diarrhea not formally a DLT but felt to be dose-limiting. The most common adverse events were GI (diarrhea reported by > 85% of pts) or infection-related (> 70% of pts)."

Excellent post by MO.

Posted On: 01/03/2019 6:21:56 PM
Posted By: Mo
The Baystreet article that BooDog posted #52509 is a MUST read. Here are some great points from the article.
===========================================================================
“There are many more similarities between these two companies that portend success and lend support to the notion that IPIX is arguably undervalued.”

“Galera and IPIX are certainly looking in the right direction in targeting head and neck cancer patients receiving chemoradiation, a treatment regimen where the incidence of SOM is stunningly high at over 70 percent. Moreover, there are no FDA-approved therapies for treating SOM in solid tumors, creating a pervasive area of high unmet medical need and a market estimated in excess of $2 billion.”

“In the case of GC4419 (Galera) for SOM, the drug is delivered intravenously.”

“oral drugs are the preferred method of administration for patients compared to laying there while the drug slowly drips through an IV. To that point, an oral drug is far more convenient, with administration available in an array of settings compared to IV. It also less expensive, likely making it the preferred method of not only insurance companies, but also doctors writing the prescriptions.”

"In the IPIX trial, treatment with Brilacidin in the modified Intent-to-Treat (mITT) population reduced the relative incidence of SOM by 65.0% compared to placebo. In the Per Protocol population, the relative incidence of SOM decreased by 80.3% compared to placebo. It bears repeating that, while the sample size was small for this group, treatment with Brilacidin oral rinse lowered the rate of SOM by over 80%."

“Innovation Pharma needs to find this quality of financial partners, but the lack of them at this point by no means justifies its paltry market capitalization of $18 million.

“For publicly-listed IPIX, whatever weight has been holding the stock down may finally be lifted so that the company can achieve a fair valuation alongside its money-raising peer so that the stock can rise from its current depressed level.”

http://www.baystreet.ca/stockstowatch/5021/A-Look-at-New-Oral-Mucositis-Drugs-Galera-Therapeutics-Capital-Raise-Points-to-Innovation-Pharmaceuticals-Being-Grossly-Undervalued


The article also made it onto yahoo as mentioned by Focusakker but I didn't see any comments.

https://finance.yahoo.com/news/look-oral-mucositis-drugs-galera-192000189.html


And, let's not forget solidifying Brilacidins future with this weeks patent news.
https://finance.yahoo.com/news/innovation-pharmaceuticals-receives-brilacidin-patent-140000771.html

The “Issue Notification” of the patent (Projected U.S. Patent Number 10166232) covers Brilacidin in the form of a pharmaceutical composition containing water. The pharmaceutical composition can also contain Tris-buffered saline. The patent covers Brilacidin in combination with additional medicaments, such as: an antibiotic, an anti-inflammatory agent, an anesthetic agent, an anti-allergic agent, an acetylcholine blocking agent, an adrenergic agonist, a beta-adrenergic blocking agent, an anti-glaucoma agent and an anti-hypertensive agent.

The new patent builds on the “Notice of Allowance” directed to Brilacidin, including oral, buccal, and sublingual pharmaceutical compositions of Brilacidin.

“As Brilacidin continues to show compelling therapeutic benefits across multiple indications, the Company is taking the necessary steps to broaden the asset’s intellectual property estate,” commented Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “Brilacidin is a unique drug candidate with the potential to be useful in numerous clinical indications alone or in combination with other medications or agents. This important new patent helps ensure we are positioning the Brilacidin franchise for future successes as we plan to advance Brilacidin into additional clinical trials, including pivotal studies for oral mucositis in 2019, with the end goal of commercialization.”

farrell90 Member Level Thursday, 01/03/19 12:57:01 AM
Re: loanranger post# 253236 0
Post # of 253378



Great news regarding the patent for ophthalmic and otic drug formulations. Hopefully IPIX will launch clincal trials to confirm their efficacy. The market for ophthalmic and otic pharmaceuticals is very large and will make a nice addition to Brilacidins other indications.

More icing on the cake.

Farrell



https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742993/

https://www.transparencymarketresearch.com/pressrelease/ophthalmic-drugs-market.htm